CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

LB Pharmaceuticals Expects Phase-3 Schizophrenia Study's Topline Data in H1 2027

Phase 3Neutral
AI Analysis

Summary

LB Pharmaceuticals announced it expects topline data from a Phase 3 schizophrenia study in the first half of 2027.

Clinical Trial Data

Phase

Phase 3

Importance:6/10
Sentiment:
0.00
Phase 3SchizophreniaClinical TrialData Readout
Related Companies

Read the original article

Published by yahoo_finance on July 22, 2026 12:54 PM

Read Original